Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Conditions:   Head and Neck Basaloid Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7;   Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7;   Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVB Nasal Cavity and Paranasal Sin us Squamous Cell Carcinoma AJCC v7;   Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7;   Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Ce ll Carcinoma AJCC v7;   Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7;   Stage IVC Oropharyngeal Squa...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

AbstractHead and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals – the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab – for the treatment of pa...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Conditions:   Head and Neck Basaloid Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7;   Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7;   St...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Squamous cell carcinoma (SCC) is the most common malignancy of head and neck region arising from mucosal linings of the upper aerodigestive tract, comprising (1) nasal cavity and paranasal sinuses, (2) nasopharynx, (3) hypopharynx, larynx, and trachea, and (4) oral cavity and oropharynx [1,2]. Head and neck squamous cell carcinomas (HNSCC) are characterized by high morbidity and mortality rates and strong tendency to regional and distant metastasis [1–4]. These tumor characteristics depend on individual properties of neoplastic cells and tumor microenvironment, which is comprised by diverse inflammatory/immune cells ...
Source: Oral Oncology - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Erbitux | Head and Neck Cancer | HNSCC | Nasal Cavity and Paranasal Sinus Cancer | Nasopharyngeal Cancer | Oral Cancer | Oral Cavity Cancer | Oropharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma